RBC Capital raised the firm’s price target on Cytokinetics (CYTK) to $82 from $80 and keeps an Outperform rating on the shares. Given the potential advantages that the company’s aficamten may have on efficacy, as well as the convenience of the drug, aficamten is likely to do better than Bristol Myers’ (BMY) Camzyos, the analyst tells investors in a research note. RBC adds that it expects a strong launch that can provide line of sight to a greater than $3.6B opportunity.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 55% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on CYTK:
- Cytokinetics opens enrollment for COMET-HF Phase 3 trial
- Cytokinetics announces FDA acceptance of NDA for aficamten
- Cytokinetics price target raised to $103 from $99 at Mizuho
- Bayer Secures Deal for Cytokinetics’ Heart Drug in Japan
- Cytokinetics partnership demonstrates value of aficamten, says JMP Securities